Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc. (BIIB) came out with quarterly earnings of $3.40 per share, beating the Zacks Consensus Estimate of $3.25 per share. This compares to earnings of $3.62 per share a year ago.

Biogen Inc. (BIIB) Beats Q1 Earnings and Revenue Estimates

Biogen stock fell early Tuesday as the company reiterated its outlook for declining sales despite its new Alzheimer's treatment. The post Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful appeared first on Investor's Business Daily.

Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful

Biogen Inc. BIIB said Tuesday it had net income of $387.9 million, or $2.67 a share, for the first quarter, up from $303.8 million, or $2.06 a share, in the year-earlier period. Adjusted per-share earnings came to $3.40, ahead of the $3.28 FactSet consensus.

Biogen tops estimates as revenue slides 3% from a year ago

Vertex Pharmaceuticals

Biogen and Vertex are both waiting on big regulatory decisions for potential products. The companies each bring in billions of dollars in revenue every year.

Better Big Biotech Buy: Biogen vs. Vertex

Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of multiple sclerosis drugs, while sales of Spinraza are likely to have improved.

Biogen (BIIB) to Report Q1 Earnings: Here's What to Expect

Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline

Biogen Inc (NASDAQ:BIIB) is buzzing today, after Piper Sandler and Wedbush praised the drugmaker ahead of the company's first-quarter earnings report -- due out before the market's open on Tuesday, April 25.

Bulls Blast Biotech Stock Before Earnings

Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.

Alzheimer's patients retain the benefits of Leqembi even when they stop the drug, Eisai says

Ionis Pharma

Ionis and Biogen have been partnering on antisense drug development for a decade. The two companies won approval for $1.8bn (in 2022) Spinraza, indicated for Spinal Muscular Atrophy.

Ionis And Biogen: Tofersen PDUFA Looms - Positive Outcome May Kick Off Bull Run For Both Stocks

Amazon

Bank of America

Bank of New York Mellon

Blackrock Inc

Comcast

CME Group

Compass Minerals

Salesforce

Corteva Inc

Disney

Domino's Pizza

Ecolab

Equifax

Emerson Electric

Etsy

Gilead Sciences

Alphabet

Harley-Davidson

Honeywell

Intercontinental Exchange

International Flavors & Fragrances

Intuit

Jack Henry & Associates

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

U.S. Wide-Moat Stocks On Sale - The April 2023 Heat Map

CAMBRIDGE, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023. Dr. Keeney will be a member of Biogen's Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer.

Biogen Appoints Adam Keeney as Head of Corporate Development

TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that three additional detailed analyses from the Phase IIb clinical study (Study 201), evaluating the efficacy and safety of lecanemab for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD), were published in the peer-reviewed journals.

Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai presented new analyses on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and caregiver burden and health-related quality of life (QOL), from the results of Eisai's Phase 3 Clarity AD study of lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti-amyloid-β (Aβ) protofibril* antibody, at the 2023 International Conference on Alzheimer's and Parkinson's Diseases annual meeting AD/PD™.

Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting

CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) reported new promising Phase 1b clinical data showing that the investigational antisense oligonucleotide (ASO) therapy, BIIB080, reduced soluble tau protein in cerebrospinal fluid (CSF) in a dose-dependent and sustained manner in patients with early-stage Alzheimer's disease (AD). BIIB080 also reduced aggregated tau pathology, as measured by positron emission tomography (PET) in all brain composites assessed. The primary endpoint of the Phase 1b trial (week 25) and open-label long-term extension study (through week 100) was safety and tolerability, with biomarker data as an exploratory endpoint. The results were presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2023) held in Gothenburg, Sweden from March 28 – April 1.

New Data Presented at AD/PD™ 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease

CGI Group

Micron Technology

QUALCOMM

BioNTech SE

Moderna

Sociedad Quimica Y Minera De Chile

Although blue-chip stocks often carry a reputation for being lumbering giants that might not kill your portfolio but certainly won't do it any favors, specific stalwarts can get the business done. In other words, these enterprises hit the sweet spot: they're tied to well-established businesses that also offer double-digit (percentage) upside potential, as determined by Wall Street analysts.

7 Blue-Chip Stocks Sitting in the Sweet Spot

The FDA committee supports an accelerated approval of Biogen's (BIIB) tofersen for treating SOD1-ALS. The committee does not believe the data supports a traditional/standard approval for tofersen.

Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA

Ionis stock jumped Thursday after an FDA panel offered a mixed view of its Biogen-partnered drug for ALS. The post Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement appeared first on Investor's Business Daily.

Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement

SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

FDA advisors voted against the effectiveness of Biogen's investigational ALS drug, which could become the first to target a genetic cause of the disease.

FDA advisors vote against effectiveness of Biogen's ALS drug for rare and aggressive form of the disease

Biogen Inc. BIIB, -1.85% received a setback late Wednesday after a Food and Drug Administration advisory committee said the biotech drug maker's proposed amyotrophic lateral sclerosis, or ALS, treatment did not show it was effective. On Wednesday, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 5-3 with one abstention that the study did not “provide convincing evidence of the effectiveness of toferson,” the name of the treatment for the proposed indication.

Biogen ALS drug considered not effective by FDA advisory panel

FDA advisors voted against Biogen's investigational ALS drug, which could become the first to target a genetic cause of the disease.

FDA advisors reject Biogen's ALS drug for rare and aggressive form of the disease

Incyte

Inspire Medical Systems Inc

Harmony Biosciences Holdings

Eli Lilly

McKesson

Merck

Stock market investors have been on a rollercoaster ride over the past year. The Federal Reserve continues to be hawkish in controlling inflation.

7 Healthcare Stocks to Buy for Long-Term Growth and Stability

It appears likely that a new drug to treat amyotrophic lateral sclerosis (ALS) will get approval in the U.S. Regulators shared their thinking ahead of an advisory committee meeting.

Wall Street predicts approval for another ALS drug

The FDA staff on Monday said Biogen's investigational ALS drug tofersen may have a "clinical benefit" on a rare and aggressive form of the disease.

FDA staff says Biogen's ALS drug may have a 'clinical benefit' on a rare form of the disease

Biogen's blockbuster drugs are losing exclusivity -- and that's weighing on earnings. The company now is counting on its latest Alzheimer's drug to turn things around.

News for Biogen Stock (BIIB)